Introduction
Proteins such as those acting as enzymes, regulatory proteins, transporters, and receptors are the active macromolecules of human biology and are thus central to understanding biological molecular processes. Understanding the diversity and complexity of these biological molecular interactions is a central focus of bio-medical research today. It is important that all protein forms of human genes are eventually studied so that their biological functions and roles in healthy and disease states can be determined [posters 17 and 18 in Table 1] 1-3 . Proteins cannot be amplified and are chemically much more heterogeneous than DNA and RNA. Their analysis therefore represents a much more significant analytical challenge.
To meet this challenge, the Human Proteome Organization (HUPO) announced in 2010 at the HUPO Congress in Sydney, Australia, the formation of the Human Proteome Project (HPP) to sequentially catalogue the protein products of human genes, both to identify proteins that have little or no evidence at the protein level, termed "missing proteins" 4, 5 , and to discover and characterize protein sequence variability with genetic origin and post-translational modifications (PTM) of known proteins. The
Chromosome-Centric Human Proteome Project (C-HPP) [4] [5] [6] is a large multidisciplinary international effort to identify all human protein forms and catalogue them on the basis of the chromosome location of their coding genes. In the C-HPP, one national or multinational team is responsible for the identification and annotation of protein products of the genes in each chromosome. Evidence at the protein level means that a protein has been detected, preferably by mass spectrometry (MS) and preferably from multiple peptides unique to the protein observed in multiple experiments and possibly in diverse biological sample types. Multiple data resources help to provide information on protein evidence.
The sharing of data, protocols, and other electronic resources such as proteome annotations is crucial in the C-HPP and proteomics community to enable the reuse of collected information (e.g., in form of high-quality spectral libraries for spectral library identification or the development of selected reaction monitoring [SRM] assays) and to develop and improve new data analysis protocols. The current status and developments in the shared proteomics data and proteome knowledge by the main stakeholders are presented below. An overview of current bioinformatics resources and the data flow to support the creation of complete part lists of the human proteome is shown in Figure 1 .
The ProteomeXchange 7 consortium, led by PRIDE 8, 9 at the European Bioinformatics Institute (Hinxton/Cambridge, UK) and by PeptideAtlas [10] [11] [12] at the Institute for Systems Biology (Seattle, Washington, USA), is devoted to the standardization of data submission and dissemination of MSbased proteomics data and to the promotion of public sharing of proteomics data in the public domain.
In addition, it promotes the use of community data standards developed by the Proteomics Standards Initiative (PSI). As such, ProteomeXchange resources store original MS datasets, containing at least the raw MS data accompanied by the processed results (peptide and protein identifications, but possibly quantitative information as well) and by suitable experimental and technical metadata. By November 2014, ProteomeXchange resources stored approximately 1500 datasets (~50% of which are publicly available) from a wide variety of sources, with humans being the most-represented species. Once the datasets are made publicly available, they are usually reprocessed by PeptideAtlas 10-12 using the Trans Proteomic Pipeline (TPP) [13] [14] [15] [16] [17] and by the Global Proteome Machine Database (gpmDB) 18, 19 using the X!Tandem 20, 21 database search tool. Basically, everyone in the community can reanalyze the raw data available in ProteomeXchange for different purposes.
To provide a comprehensive view of the human proteome and its diversity, neXtProt 22, 23 is adding information at the genomic, transcriptomic and proteomic levels to the corpus of information available in UniProtKB [24] [25] [26] . In particular, neXtProt integrates genomic variation data from dbSNP 27 41 and Figure S1 in the supporting information).
When the C-HPP began (2012), it was announced that no satisfactory evidence existed at the protein level for 6568 (33%) of the 20,059 protein-coding genes 42 . [51] [52] [53] . However, proteogenomic analysis generally results in a larger database than does using the UniProtKB canonical sequences, and should be followed through false discovery rate (FDR) analysis at both the peptide and protein levels 13, 47 , especially when the database search is performed in multiple steps 47, 54 Figure S2 in the supporting information. Importantly, unlike bottom-up protocols in which detailed information on PTMs and sequence variants is compromised because of enzymatic digestion, intact proteins are analyzed in topdown approaches, which allows the unequivocal identification and location of specific modifications.
However, they require relatively pure protein samples, they are restricted to proteins of less than 30 kDa, the available fragmentation spectra are often far from complete, and the obtained complex spectra are often difficult to interpret [64] [65] [66] [67] .
Analysis of mRNA has an advantage in that sequences can be amplified to provide nearly complete sequence coverage using current RNA sequencing technologies. The challenge is to accurately annotate the resulting raw DNA and RNA data, which is generally performed using the 73, 74 should be taken into account in the integration of proteogenomics data. The half-life difference between these two molecular species could result in proteins without mRNA when proteins and mRNA are measured in the same sample and at a single time point. Time series sampling could be used to overcome this issue, when it is possible. This is the case for cell cultures, blood or animal experiments, or tissues for which multiple samples are available from the same specimen at different time. For other cases, the use of a combined databases from translated mRNA sequences and the UniProt database is an option for the detection of proteins with a half-life much longer than that of mRNA.
Translating mRNA, which is directly upstream of protein expression, thus serves as a useful resource for protein identification 53 . Wang et al. 75 performed the first translated mRNA sequencing (RNC-seq)
in human lung cancer cell lines and observed an improved correlation of RNC-mRNA abundance with translated protein when the RNC-mRNA length was taken into consideration. The same group showed that the genes with translation evidence represent an improved reference for the identification of proteins, the detection of sequence variations (SAV, RNA editing and alternative splicing), and integration of the MS data 53 .
Furthermore, missing proteins with mRNA evidence and more stringent conditions with ribosome- In their study, three hepatocellular carcinoma cell lines (Hep3B, HCCLM3, and MHCC97H) were submitted for mRNA and RNC-mRNA analysis and to comprehensive analysis with deep proteomics and antibody-enriched transcription factor proteomics. Based on the integrated data, they concluded that only 50.2% of the protein-coding genes with translation evidence were found in the proteomic data. This result is comparable to that of a previous study on the RNC-mRNA and MS data of Caco-2 cells: 52.6% of the proteins with translation evidence were missing from the LC-MS/MS data acquired from institutions 53 . The inability to detect certain proteins by LC-MS/MS was most probably a results methods to increase protein sequence coverage (e.g., by using multiple proteases for protein cleavage 49 or by using a more efficient method of peptide fragmentation such as EThcD [86] [87] [88] ). The membrane subproteome was suggested to be a rich source of missing proteins. A deep sequencing strategy using 99 can help to select the most appropriate surrogate peptides for a given protein list in human and mouse proteomes to be used in targeted SRM assays based on the current knowledge of the community as presented in UniProtKB, PeptideAtlas, gpmDB, PRIDE and dbSNP. The tool identified has already reported peptides in online databases for missing proteins, although the quality of the data in these databases varies considerably.
The data-independent sequential window acquisition workflow (SWATH-MS) allows collection of non-targeted fragment spectra by fragmenting large windows of precursor ions (typically 20 to 25
Dam/z). The resulting MS/MS data can be reconstituted from the co-eluted fragment ions with liquid chromatography retention time using deconvolution methods. The SWATH approach also can be seen as a generalization of the SRM approach, in which each detectable fragment ion is measured and can be reconstituted from the acquired data without being restricted to a targeted list of transitions as in SRM.
Recently, SWATHAtlas was introduced, which stores a human library of MS/MS spectra acquired on a TripleTOF instrument for 10,000 human proteins 100 . This library was obtained from 331 measurements on cell lines, blood, and other human tissues and is intended to be used by PeakView, the OpenSWATH tool 101 , and other analogous processing software, providing 51% of coverage of canonical UniProtKB/Swiss-Prot 39 entries.
Another important resource for the identification of missing proteins is SRMAtlas 91 , which contains a high-confidence "gold standard" quality SRM assay for at least one unique peptide for 99.9% of the canonical UniProtKB/Swiss-Prot 39 entries. This high coverage was achieved by including MS/MS spectra obtained from a large campaign of production and analysis of synthetic peptides for the complete human proteome. Another source of MS/MS spectra and spectral libraries for phosphorylated and unmodified synthetic peptides is available for assay development 102 .
The development and application of SRM assays to complex biological samples is a well-established Antibodies are effective reagents for the specific detection and enrichment of missing proteins 103 . The availability of highly specific and validated antibodies is crucial for the detection of low abundant missing proteins and the spatial characterization of their expression pattern in cells and tissues. The implementation of high-throughput production of validated high-affinity monoclonal antibodies using automated production systems will provide renewable resources 104, 105 . SISCAPA can enhance the sensitivity of SRM analyses by enriching specific peptides [106] [107] [108] .
The HPA 31, 109 project has systematically generated affinity purified polyclonal antibodies using proteospecific recombinant protein fragment and Protein Epitope Signature Tags (PrESTs) 110 . After a rigorous validation scheme, the approved antibodies are used to assess the spatial distributions of the proteins in a multitude of human cells and tissues by immunohistochemical analysis. 113 .
In a recent collaboration between the HPA group in Stockholm and the high throughput monoclonal antibody facility at Monash University in Melbourne a number of monoclonal antibodies against missing proteins, important signaling molecules and proteins of interest to the Chromosome 7 and 17 groups were generated using the same PrESTs as immunogens, which will allow a direct comparison between monoclonal and polyclonal antibodies raised against the same prEST and generate new reagents for the proteomics community. Interestingly, in some cases it was possible to raise monoclonal antibodies to targets that had failed to generate polyclonals. This finding provides an additional route for completion of the task of generating renewable antibodies to all human proteins using the existing antigen resources. Lambert et al. 114 recently showed that coupling affinity enrichment with quantitative MS techniques such as SWATH analysis provides the most sensitive detection method for low abundant missing proteins.
Human sample resources
Human samples are collected and stored in various locations worldwide and are crucial to the C-HPP project and to proteomics and disease research in general. Even if sensitive analytical methods are available to uniquely identify and detect missing proteins, high-quality human samples collected under strict standard operating procedures for collection, processing, and storage must be available to characterize protein expression. Although many countries have recognized this need and have established biobanks for the collection and storage of human samples available from local or regional resources, they have not always been collected under the optimal conditions required for the maintenance of the initial integrity of the protein constituent of samples for proteomics studies. Here, many factors leading to protein degradation need to be identified and addressed by the community.
Therefore, as demonstrated by several groups [115] [116] [117] [118] [119] [120] [121] , sample collection and storage protocols should be assessed and optimized in this respect for each sample type. For the C-HPP initiative, in addition to ensuring the sample quality, it is also important to exchange samples between laboratories in different countries, for which legal and ethical regulations should be in place. To facilitate the exchange of samples, HUPO will join forces with ISBER 122, 123 , an international organization that has worked out regulatory and ethical protocols and Best Practice guidelines 124 for such purposes.
Controlled vocabularies and ontologies pioneered by SNOMED 125 providing standardised anatomical descriptors related to tissue types (BRENDA) 126, 127 , cell types (Cell Ontology) 128 , and human diseases (DOID, http://disease-ontology.org/) 129 72 and Wilhelm et al. 131 by Ezkurdia et al. 132 showed that these two large-scale studies with poor MS/MS spectra identified more than 100 olfactory receptors, despite the fact that they did not include data from nasal tissue. This quality assessment shows the importance of critical error analysis of peptide and protein identification in large-scale data analysis projects. The use of a 1% threshold for FDR limited only to PSM or peptide levels is not sufficient to provide a high-quality list of identified proteins in large aggregated datasets. Therefore the statistical criteria must be a 1% FDR or better calculated at the protein level for the combined dataset as adopted by PeptideAtlas 11, 17 . Using a 1% FDR threshold at the PSM or peptide level would result in a large number of misidentified or indistinguishable proteins when analyzing a large amounts of data.
These incorrect PSMs map to proteins randomly, which results in a greater FDR at the protein level.
Setting an FDR should take into account the number of identified peptides and proteins in large datasets. For example, if a million PSM pass a threshold of 1% FDR, this implies that there are 10,000
false PSMs, and these tend to map to proteins with one peptide per protein, which results in large FDR at the protein level. For datasets from which 3000 proteins are identified, a 1% protein-level FDR implies only 30 incorrect protein identifications. However, for very large datasets from which 15,000
proteins are identified, a 1% protein-level FDR would result in 150 misidentified proteins, which is a considerable number. In this case, lowering the FDR to 0.1% for example, would keep the number of misidentified proteins at more acceptable number of approximately 15. C-HPP will stringently identify olfactory receptors in nasal tissue accompanied with thorough FDR analysis at the PSM, peptide and protein levels.
Bioinformatics resources
High-level bioinformatics support is crucial for the success of the C-HPP initiative and goes beyond the [139] [140] [141] . These resources are currently being developed in isolation, which makes it difficult to further interrogate the diverse types of information stored in these resources. With the participation of the major database developers listed previously (Figure 1) , an initiative to create at Unified Human Proteome Browser [poster 16] as an advanced knowledge-mining system was established at HUPO 2014 in Madrid. This builds on the strengths of existing browsers and their development teams to provide a unified platform for further detailed analysis of the acquired proteogenomic data from the perspectives of chromosomes, biology, and disease. This will lead to a better overview of the existing proteogenomic information that can be developed to suit the needs of the global proteomics community and to improve the current standards of data processing, visualization, and interpretation. It will be essential to subject the component resources and their overall performance to comparisons of assumptions, methods, or findings.
The importance of the quality of bioinformatics workflows and use of false-discovery thresholds was demonstrated by Eric Deutsch, who showed that the addition of four large datasets (the CPTAC repository 142 and those of Kim et al. 72 , Wilhelm et al. 131 , and Guo et al. 143 ) to PeptideAtlas 11, 12, 91 only increased the amount of level 1 protein evidence for approximately 1365 neXtProt entries using stringent error thresholds of 0.000091 FDR for PSMs, 0.00028 FDR at peptide level, and 0.011 FDR at protein level identification. The successive increments in HumanAll build database of PeptideAtlas from these new large studies were 541, 591, 231, and 2 proteins. gpmDB, PeptideAtlas, and neXtProt each estimated the high-quality protein identifications from Kim et al. 39 and Wilhelm et al. 60 to be about 13,000, not 17,294 or 18,059, as reported. Further scientific scrutiny of the many reasons for these large discrepancies will be desirable, involving all parties, as launched in Madrid.
The proteomics community has a great deal of experience with over-calling protein identifications when stringent FDR thresholds are not maintained. The sensitivity to protein matching protocols can be illustrated with the results from the HUPO Human Plasma Proteome Project (HPPP). The original HPPP team paper 144 highlighted a "core dataset" of 3020 proteins with two or more peptide matches, but clearly delineated a broad range of values with other criteria. In contrast, States et al. 145 missing protein-coding genes were expressed at the mRNA level in at least one sample, and that the majority of the genes showed sample specificity. Their study confirmed that the missing proteins are typically shorter and of lower abundance than those that have been identified. Transmembrane, cytoskeleton, signal transduction, spermatogenesis, zinc finger domains, synapses, neurotransmitter activity, and olfactory transduction are enriched cellular functions among the missing proteins 148 . All of these data will be available in the dasHPPboard webtool (http://sphppdashboard.cnb.csic.es/) [poster 10], which has the goal of creating a similar initiative for storing and accessing the processed data generated by the C-HPP projects in a manner similar to that of ENCODE 46, 47 .
To support the C-HPP initiative, Islam et al. 107 missing proteins, with evidence for an additional 15 missing proteins using the data of a recent membrane proteomic study 149 .
NeXtProt provides primarily web-based protein evidence information, but also enables retrieval of data in various output formats (HTML, JavaScript Object Notation [JSON] and XML) using the REST Application Programming Interface (www.nextprot.org/rest/). In addition, neXtProt provides "chromosome reports" on its ftp server to support C-HPP projects. At the workshop in Segovia, the neXtProt team announced the development of an advanced search engine based on SPARQL that will enable complex and powerful queries, including federated queries with external resources 151 .
Conclusions
The reduction of the proportion of missing proteins in the human proteome from 33% to 18% (or 15%)
over the last four years shows the clear progress of the C-HPP, which is mainly due to the application of improved proteomics technology such as specific sample preparation (e.g., antibody-based enrichment and enrichment of hydrophobic peptides), the use of advanced spectrometers, the application of SRM and SWATH assays for missing proteins [poster 3 and 14], and the analysis of unusual human sample types [posters 6, 7, 11, 13, and 15]. As the results approach saturation of the parts list for protein-coding genes, it will be ever more important to apply stringent FDR criteria to the claims of protein matches and to confirm the findings with orthogonal methods. "One-hit wonders,"
especially of short peptides, and claims of matches in tissue or cell types without transcript expression or that have not previously shown evidence of such proteins with modern instruments should be viewed with skepticism. The quality of the spectra must be examined, keeping in mind that when Ezkurdia et al. 132 examined the spectra for hundreds of olfactory receptor proteins claimed by Kim et al. 72 and by
Wilhelm et al. 131 , none survived scrutiny. Likewise, peptides with multiple matches may be more likely to represent known, highly expressed proteins with a single mutation or an RNA-edited site than a "missing protein." The C-HPP has also encouraged analyses of amplicons (cis-regulated genes in specific chromosomal segments) and of protein families, as well as the recognition of proteins that are unlikely to be detected for the reasons outlined in Figure 2 .
Proteogenomic analysis integrating data from genomics, transcriptomics, and proteomics is gaining It is clear that work must still be undertaken to confirm the presence of the remaining missing proteins, which will become more and more challenging as the completion of the MS-based evidence of the human proteome on the gene basis is reached. C-HPP members are increasing their activities to find evidence for the remaining missing human proteins and to discover more and more complete sets of protein forms that reflect genetic variability and post-translational modifications.
The C-HPP posters presented at HUPO 2014 in Madrid ( Table 1 . List of posters presented at C-HPP poster session on 7 October 2014 at HUPO 2014 (Madrid), and used as second reference (poster number) in this paper.
